Please assess the completion status of the following clinical trial:

Trial Title: Extension Study of V72P13 to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered as a Booster or as a Two-dose Catch-up to Healthy Toddlers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 8.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy 12-month-old toddlers (0/ +29 days) who completed Study V72P13~Exclusion Criteria:~* Previous ascertained or suspected disease caused by N. meningitidis;~* History of severe allergic reaction after previous vaccinations or hypersensitivity to any vaccine component;~* Any serious chronic or progressive disease~* Known or suspected impairment/ alteration of the immune system,~* Receipt of, or intent to immunize with another vaccine, within 30 days prior to enrollment.

- Gender: ALL
- Minimum Age: 365 Days
- Maximum Age: 394 Days
- Healthy Volunteers: t

Study Arms:
- 12B12M (1a) (Type: EXPERIMENTAL): Previously in the parent study subjects had received three doses of rMenB+OMV NZ and routine vaccine at 2, 4 and 6 months of age,respectively. These subjects received a booster (fourth) dose at 12 months of age concomitantly with one dose of MMRV vaccine in the present study.
- 12B13M (1b) (Type: EXPERIMENTAL): Previously in the parent study subjects had received three doses of rMenB+OMV NZ and routine vaccine at 2, 4 and 6 months of age, respectively. These subjects received a booster (fourth) dose at 12 months and one dose of MMRV vaccine at 13 months of age in the present study.
- 12M13B15B (2a) (Type: EXPERIMENTAL): Previously in the present study subjects had received routine vaccine at 2, 4 and 6 months of age respectively. These subjects received MMRV vaccine at 12 months of age and two catch-up doses of rMenB+OMV NZ vaccine at 13 and 15 months of age in the present study.
- 12M12B14B (2b) (Type: EXPERIMENTAL): Previously in the parent study subjects ahd received three doses of routine vaccine at 2, 4 and 6 months of age, respectively. These subjects received two catch-up doses of rMenB+OMV NZ at 12 and 14 months of age and one dose of MMRV vaccine given concomitantly at 12 months of age in the present study.
- 12B12M (3a) (Type: EXPERIMENTAL): Previously in the parent study subjects had received three doses of rMenB+OMV NZ at 2, 4 and 6 months of age respectively. These subjects had received one booster (fourth) dose of rMenB+OMV NZ at 12 months of age concomitantly with one dose of MMRV vaccine in the present study.
- 12B13M (3b) (Type: EXPERIMENTAL): Previously in the present study subjects had received three doses of rMenB+OMV NZ at 12 months of age respectively. These subjects one booster (fourth) dose of rMenB+OMV NZ at 12 months of age and one dose of MMRV vaccine at 13 months of age in the present study.
- 12B12M_C (4a) (Type: EXPERIMENTAL): Previously in the parent study subjects had received three doses of Meningococcal C vaccine and routine vaccine at 2, 4 and 6 months of age respectively. These subjects had received one single dose of rMenB+OMV NZ at 12 months of age concomitantly with one dose of MMRV vaccine in the present study.
- 12B13M_C (4b) (Type: EXPERIMENTAL): Previously in the parent study subjects had received three doses of Meningococcal C vaccine and routine vaccine at 2, 4 and 6 months of age. These subjects received one single dose o rMenB+OMV NZ at 12 months of age and one dose of MMRV vaccine at 13 months of age in the present study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete